STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #34 by analyst upside · 2026-06-27
AIM
AIM ImmunoTech Inc.
Healthcare · Market Cap $9M · P/E 0x
ANALYST PRICE TARGET
+1582.2%
implied upside to consensus target
Current Price $0.31
Consensus Target $5.25
Bull Target $9.0
Bear Target $1.5
Analysts Covering 2
ANALYST CONSENSUS — BUY
Strong Buy
0
Buy
2
Hold
0
Sell
0
52-Week Low $0.21
52-Week High $19.74
YTD Return -73.0%
FUNDAMENTALS
Market Cap $9M
P/E Ratio (TTM) N/A
Forward P/E -0.6x
EPS (TTM) $-4.31
PEG Ratio 0.71
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.21
52-Week High $19.74
Current Price $0.31
Bear Target $1.5
Bull Target $9.0
● Now $0.31 ● Target $5.25
TRADING DATA
Avg Volume 27.3M
YTD Return -73.0%
Analyst Count 2
Consensus Buy
Upside to Target +1582.2%
Last Updated 2026-06-27

ANALYST SUMMARY

AIM ImmunoTech Inc. (AIM) is currently trading at $0.31 with a Wall Street consensus price target of $5.25, implying potential upside of 1582.2% over the next 12 months. 2 analysts currently cover AIM, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $9.0, while the most cautious has a target of $1.5.

AIM operates in the Healthcare sector with a market capitalisation of $9M. The stock is down 73.0% year-to-date and is currently trading near the lower end of its 52-week range of $0.21 – $19.74.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for AIM, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Ascendiant Capital — Reiterated
Buy → Buy 2026-06-01 Building track record
Ascendiant Capital — Reiterated
Buy → Buy 2026-04-10 Building track record
Ascendiant Capital — Reiterated
Buy → Buy 2025-12-08 Building track record
Ascendiant Capital — Reiterated
Buy → Buy 2025-10-03 Building track record
Ascendiant Capital — Reiterated
Buy → Buy 2024-12-10 Building track record
Maxim Group — Reiterated
Buy → Buy 2024-10-22 28% win rate (40 calls)
Ascendiant Capital — Reiterated
Buy → Buy 2024-09-03 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →